Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Content Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostBy Chris Markoch. Originally Published: 2/5/2026. 
Key Points - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 drug candidate. Almost no one sees it coming, but AI is about to split America into two over the next 12 months. On one hand, it'll make America's one-percenters richer and more powerful than ever. On the other hand, it's set to trap millions of hardworking Americans in financial quicksand. Former Google exec Kai-Fu Lee says AI could wipe out 50% of jobs by 2027. Elon Musk has said AI will surpass human intelligence by 2027. Mark Zuckerberg has said half of all coding could be done by AI within the next year. One ex-hedge fund manager whose team predicted Nvidia's rise in 2020 calls this the AI End Game, and he says there are three critical moves every American should make in the next 12 months to protect and grow their wealth through this paradigm shift. See the three moves before the AI split happens PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That story starts with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data show the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035. That's a compound annual growth rate (CAGR) of 9.7% and explains why billions of dollars are flowing into the industry from companies trying to carve out market share. For Pfizer, that opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after switching from weekly to monthly dosing, with no plateau observed by the end of the 28-week period. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom pointed to the positive clinical trial results as the reason for the stock's gain. That may be true, but investors should be aware that the GLP-1 excitement can be a near-term boost rather than a long-term guarantee. While Pfizer's GLP-1 candidate shows promise, it will take time for those results to materially impact the company's revenue. And the GLP-1 trade is expanding: as the earnings report from Eli Lilly & Co. (NYSE: LLY) shows, large pharma competitors aren't planning to give up leadership in obesity drugs anytime soon. However, there are other reasons to be bullish on PFE—chief among them Pfizer's oncology portfolio. Data from Business Research Insights values the global oncology drugs market at approximately $264.92 billion in 2026 and projects it to climb to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer has roughly 60 candidates in its product portfolio, translating to many opportunities to capture market share. The company's pipeline was significantly enhanced after its acquisition of Seagen in 2023. Today, Pfizer's portfolio includes both late-stage candidates and next-generation modalities. Examples include Vepdegestrant, a targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, which are being evaluated against ER+/HER2- metastatic breast cancer in later-stage trials. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, which targets bladder cancer; and the bispecific PD-1xVEGF agent PF-4404, being studied in combination with Padcev to treat urothelial cancer—positioning these programs for potential blockbusters amid oncology growth.
Pfizer could bring multiple drugs to market over the next five to 10 years. That potential is amplified by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics—efforts that speed target identification and candidate selection. Internal platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing. These efforts were critical to the company's rapid development of Paxlovid and support 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity by 35% to 45% by refining preclinical decisions and clinical trials, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself near the forefront of AI adoption, which should provide a meaningful tailwind for investors over the medium and long term.
| 
